You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(9926.HK)上市第二日繼續大漲13.17% 在研產品管線亮眼
格隆匯 04-27 16:16
格隆匯4月27日丨繼上週五首日上市收漲50.19%後,康方生物-B(9926.HK)今日繼續上漲,最終收漲13.17%報27.5港元,收盤價為上市最高價,最新總市值210億港元。該股目前價格較16.18港元發行價暴漲70%。 

據悉,康方生物雖然目前還未盈利,但相較於其他未盈利生物科技類公司產品管線較多,產品技術含量高,並且呈現多元化。
公司目前共擁有20多個藥物開發項目,其中12個抗體處於臨牀階段,6個雙特異性抗體(兩個處於臨牀階段)以及4個抗體獲得FDA的IND批准。自2017年以來,公司已就創新候選藥物啟動22項臨牀試驗。公司研發管線涵蓋了PD-1、CD47、CD73、IL-12/IL-23、IL-17、IL-4R等與腫瘤免疫治療和自身免疫相關的熱門靶點。
此外,產品的組合形式也比較多樣,有單克隆抗體,單抗與其他藥物聯合的combo,還有一系列全球首創處在臨牀開發階段的雙特異性抗體。 
還值得注意的是,康方生物具有很強的商業合作能力。曾於2015年向Merck授權了一種CTLA-4抗體(AK107),總對價高達2億美元。2019年6月,又與中國生物製藥(1177.HK)的主要附屬公司正大天晴成立合營公司,共同開發PD-1抗體候選藥物(penpulimab(AK105))並全力推動其註冊上市及產業化進程。 
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account